Ovarian cancer with high-level focal ERBB2 amplification responds to trastuzumab and pertuzumab

Laure Thouvenin,Mélinda Charrier,Sophie Clement,Yann Christinat,Jean-Christophe Tille,Mauro Frigeri,Krisztian Homicsko,Olivier Michielin,Alexandre Bodmer,Pierre O. Chappuis,Thomas A. McKee,Petros Tsantoulis

Gynecologic Oncology Reports（2021）

引用 6|浏览5

暂无评分

摘要

•Trastuzumab monotherapy has limited efficacy in ovarian cancer.•The combination of trastuzumab and pertuzumab has not been studied adequately.•An ERBB2-amplified ovarian carcinoma had a durable response to this combination.•High-level focal amplification may be a valuable biomarker predicting response.

查看译文

关键词

Ovarian cancer,ERBB2 amplification,Trastuzumab,Pertuzumab,Precision oncology

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要